Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform.

Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform.
复制标题

DOI:
10.1016/j.cca.2013.05.001
复制
发表时间:
2013-09-23
期刊:
Clinica chimica acta; international journal of clinical chemistry
影响因子:
--
通讯作者:
Pamula VK
Pamula VK
中科院分区:
其他
文献类型:
--
作者:
Sista RS;Wang T;Wu N;Graham C;Eckhardt A;Winger T;Srinivasan V;Bali D;Millington DS;Pamula VK

文献摘要

参考文献

被引文献

相似文献

溶酶体贮积病 (LSD) 的新疗法引起了人们对新生儿筛查这些疾病的兴趣。我们在数字微流体平台上提供了性能验证数据,该平台对庞贝病、法布里病、亨特病、戈谢病和 Hurler 病进行多重酶测定。我们开发了一种研究性一次性数字微流体盒,它使用单个干血点 (DBS) 打孔器对多达 44 个 DBS 样品进行 5 重荧光酶测定。通过分析质量控制 DBS 样品来确定测定的精度和线性度;通过分析 600 个假定正常和已知受影响的样本(Pompe 12 个,Fabry 7 个,Hunter、Gaucher 和 Hurler 各 10 个)来确定临床表现。墨盒、天数、仪器和操作员之间的总体变异系数 (CV) 值在 2% 到 21% 之间;所有测定的线性相关系数均≥ 0.98。从单个 DBS 打孔机进行的多重酶测定能够区分 5 个 LSD 的假定正常样本和已知受影响样本。数字微流体技术显示出在新生儿筛查实验室环境中快速、高通量筛查 5 种 LSD 的潜力。每个柱上从样品制备到酶活性的时间不到 3 小时。
New therapies for lysosomal storage diseases (LSDs) have generated interest in screening newborns for these conditions. We present performance validation data on a digital microfluidic platform that performs multiplex enzymatic assays for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases. We developed an investigational disposable digital microfluidic cartridge that uses a single dried blood spot (DBS) punch for performing a 5-plex fluorometric enzymatic assay on up to 44 DBS samples. Precision and linearity of the assays were determined by analyzing quality control DBS samples; clinical performance was determined by analyzing 600 presumed normal and known affected samples (12 for Pompe, 7 for Fabry and 10 each for Hunter, Gaucher and Hurler). Overall coefficient of variation (CV) values between cartridges, days, instruments, and operators ranged from 2 to 21%; linearity correlation coefficients were ≥ 0.98 for all assays. The multiplex enzymatic assay performed from a single DBS punch was able to discriminate presumed normal from known affected samples for 5 LSDs. Digital microfluidic technology shows potential for rapid, high-throughput screening for 5 LSDs in a newborn screening laboratory environment. Sample preparation to enzymatic activity on each cartridge is less than 3 hours.
DOI: 10.1053/j.semperi.2009.12.008
发表时间: 2010-04
影响因子: 3.4
作者:
Millington DS;Sista R;Eckhardt A;Rouse J;Bali D;Goldberg R;Cotten M;Buckley R;Pamula V
通讯作者: Pamula V
DOI: 10.1373/clinchem.2010.152009
发表时间: 2010-12-01
期刊: CLINICAL CHEMISTRY
影响因子: 9.3
作者:
Duffey, Trisha A.;Bellamy, Garland;Scott, C. Ronald
通讯作者: Scott, C. Ronald
DOI: 10.1373/clinchem.2008.111864
发表时间: 2009-01-01
期刊: CLINICAL CHEMISTRY
影响因子: 9.3
作者:
De Jesus, Victor R.;Zhang, X. Kate;Hannon, W. Harry
通讯作者: Hannon, W. Harry
DOI: 10.1016/s0140-6736(11)61266-x
发表时间: 2012-01-28
期刊: LANCET
影响因子: 168.9
作者:
Mechtler, Thomas P.;Stary, Susanne;Kasper, David C.
通讯作者: Kasper, David C.
DOI: 10.1373/clinchem.2011.163139
发表时间: 2011-10-01
期刊: CLINICAL CHEMISTRY
影响因子: 9.3
作者:
Sista, Ramakrishna S.;Eckhardt, Allen E.;Pamula, Vamsee K.
通讯作者: Pamula, Vamsee K.